Loading…
Employees: 1,744
Size GuangYuYuan Chinese Herbal Medicine (600771.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $930M, the 2443rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.73 on 6 Nov 2026.
Performance Over six months the shares fell 24.1%, against -12.8% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue fell 5.5% over the last twelve months (peer median +5.1%); the operating margin is 4.5% (peer median 2.5%).
Valuation It trades at 41.1× forward earnings against a peer median of 24.7× (most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.3 points below its cost of capital (9.9% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.31B | CN¥1.35B | CN¥1.20B | CN¥1.27B | CN¥1.12B |
| Revenue growth | — | +12% | -5% | +14% | — |
| Gross profit | CN¥891M | CN¥882M | CN¥861M | CN¥899M | CN¥734M |
| EBITDA | n/a | CN¥170M | CN¥144M | CN¥154M | -CN¥187M |
| Net income | CN¥63.2M | CN¥63.0M | CN¥74.5M | CN¥90.1M | -CN¥250M |
| Free cash flow | CN¥216M | CN¥191M | CN¥103M | CN¥214M | CN¥246M |
| Capital expenditure | CN¥7.60M | CN¥6.24M | CN¥8.78M | CN¥2.51M | CN¥8.67M |
| Total debt | CN¥41.4M | CN¥63.0M | CN¥77.8M | CN¥333M | CN¥564M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600771.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.1% | -7.3% | 9th lowest of 20 |
| 6-month return | -24.1% | -12.8% | 7th lowest of 20 |
| Distance from 52-week high | -37.6% | -31.4% | 7th lowest of 21 |
| Revenue growth (TTM) | -5.5% | +5.1% | 7th lowest of 18 |
| Operating margin | 4.5% | 2.5% | 8th highest of 18 |
| Forward P/E | 41.1× | 24.7× | most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 33.2% | 16.2% | most demanding of 8 |
| Growth delivered (Del g) | +4.2% | +7.8% | 4th lowest of 8 |
| Hurdle (Req g minus delivered) | +29.0 pp | -3.8 pp | 2nd most demanding of 8 |
| ROIC minus cost of capital | -4.3 pp | -2.5 pp | 7th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 41.1× | 33.2% | +4.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | n/a | n/a | n/a |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 27.5× | 16.7% | +27.7% |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | n/a | -1.2% | -39.5% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | n/a | 16.2% | -0.2% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 30.6× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | n/a | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 24.7× | 5.5% | +9.3% |
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 12.0× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 15.5× | 18.1% | +7.8% |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | n/a | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |